Medicine-taking behaviour in schizophrenia - part 1
نویسندگان
چکیده
منابع مشابه
Language in Schizophrenia Part 1: An Introduction
This is the first of two articles that discuss higher-order language and semantic processing in schizophrenia. This article reviews clinical characterizations of language output and the phenomenon of positive thought disorder, as well as more principled characterizations of language output in schizophrenia. It also gives an overview of evidence for the predominant theory of language dysfunction...
متن کاملPersonalized Medicine, Part 1: Theranostics
HISTORY AND LANDSCAPE Over the past six decades, much evidence has emerged indicating that a substantial portion of variability in drug response is genetically determined, with age, nutrition, health status, environmental exposure, epigenetic factors, and concurrent therapy playing important contributory roles. To achieve individual drug therapy with a reasonably predictive outcome, one must fu...
متن کاملRisk-taking behaviour of Cape Peninsula high-school students. Part VII. Violent behaviour.
The prevalence of a wide range of risk-taking behaviour among high-school students in the Cape Peninsula, South Africa, was investigated. In this article, the results for violent behaviour are presented. Cluster sampling techniques produced a sample of 7,340 students from 16 schools in three major education departments. A self-administered questionnaire was completed in a normal school period. ...
متن کاملHerbal Medicine in the Treatment of Schizophrenia: A Review
As a chronic psychiatric disorder, schizophrenia affects the worldwide population with a lifetime prevalence of 1% and considerable long-term mortality, morbidity, and burden. Besides the adverse effects of routine treatment regimens, a significant portion of patients remain symptomatic despite treatment, especially those with negative symptoms which are the major disabling factors in these pat...
متن کاملTaking Personalized Medicine Seriously: Biomarker Approaches in Phase IIb/III Studies in Major Depression and Schizophrenia.
The success rate in the development of psychopharmacological compounds is insufficient. Two main reasons for failure have been frequently identified: 1) treating the wrong patients and 2) using the wrong dose. This is potentially based on the known heterogeneity among patients, both on a syndromal and a biological level. A focus on personalized medicine through better characterization with biom...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Progress in Neurology and Psychiatry
سال: 2010
ISSN: 1367-7543
DOI: 10.1002/pnp.167